Mirna Therapeutics Appoints CSO
This article was originally published in Scrip
Mirna Therapeutics has appointed Miguel Barbosa executive vice-president and chief scientific officer. Barbosa previously served in leadership roles at various Johnson & Johnson (J&J) subsidiaries and most recently he was executive in residence, therapeutic innovation at J&J Innovation. Prior to this he was vice-president of immunology research and external innovation at another J&J company, Janssen Research and Development LLC.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.